These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 494630)

  • 1. [Fibrin degradation products in the urine in diabetic nephropathy].
    Khristov V; Apostolov P; Stamenova T
    Vutr Boles; 1979; 18(4):32-6. PubMed ID: 494630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fibrin fibrinogen degradation products in the urine and blood in patients with diabetes mellitus and renal complications].
    Astrug A; Shipkova P
    Vutr Boles; 1982; 21(5):81-8. PubMed ID: 7164412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Urinary cross-linked FDP in various renal diseases].
    Inuma H
    Nihon Jinzo Gakkai Shi; 1994 Feb; 36(2):146-57. PubMed ID: 8139147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific identification of urinary fibrinogen, fibrinogen degradation products, and cross-linked fibrin degradation products in renal diseases and after renal allotransplantation.
    Scott WL; Francis CW; Knutson DW; Marder VJ
    J Lab Clin Med; 1986 Jun; 107(6):534-43. PubMed ID: 3519810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical significance of urinary fibrin/fibrinogen degradation products in renal disease. Second report: Urinary fibrin/fibrinogen degradation products in nephrotic syndrome. (author' transl)].
    Miyamura S
    Nihon Jinzo Gakkai Shi; 1978 Apr; 20(4):315-26. PubMed ID: 671855
    [No Abstract]   [Full Text] [Related]  

  • 6. Significance of urinary fibrin/fibrinogen degradation products (FDP) D-dimer measured by a highly sensitive ELISA method with a new monoclonal antibody (D-D E72) in various renal diseases.
    Shibata T; Magari Y; Kamberi P; Ishii T; Tomo T; Yasumori R; Nasu M
    Clin Nephrol; 1995 Aug; 44(2):91-5. PubMed ID: 8529315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical significance of urinary FDP-E measured by latex photometric immunoassay (LPIA) in the renal disease].
    Kaizu K; Ito Y; Uriu K; Komine N; Hashimoto O; Eto S
    Nihon Jinzo Gakkai Shi; 1991 Apr; 33(4):365-71. PubMed ID: 1875556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Urinary-plasmin alpha 2 plasmin inhibitor complex (PIC) in patients with diabetic nephropathy].
    Saigo K; Ryo R; Yamaguchi N
    Rinsho Byori; 1993 Jul; 41(7):785-8. PubMed ID: 8361049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of urinary fibrin/fibrinogen degradation products (FDP) as measured by latex photometric immunoassay in renal diseases.
    Kaizu K; Ito Y; Uriu K; Eto S
    Nihon Jinzo Gakkai Shi; 1993 Jan; 35(1):29-34. PubMed ID: 8336397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Urine fibrin degradation products in detection and management of acute and chronic renal transplant rejection.
    Cattran DC; Hockley M; Fenton SS; Wilson DR
    Clin Nephrol; 1977 Jun; 7(6):255-61. PubMed ID: 326454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antithrombin III and fibrinogen degradation product (fragment E) in diabetic nephropathy.
    Chan V; Yeung CK; Chan TK
    J Clin Pathol; 1982 Jun; 35(6):661-6. PubMed ID: 7085916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Urinary fibrinogen degradation products and differential protein clearances in renal disease.
    Blainey JD; Terry JM
    Clin Nephrol; 1979 Mar; 11(3):140-1. PubMed ID: 436342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of urinary excretion of fibrin degradation products during treatment of glomerulonephritis.
    Michielsen P; Roels L; Vanrenterghem Y; Boel A; van Damme B; Vermylen J
    Clin Nephrol; 1976 Mar; 5(3):105-13. PubMed ID: 1261101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Determination of fibrin and fibrinogen split products by their anticoagulant activity].
    Belitser VA; Varetskaia TV; Tsynkalovskaia SN; Tsariuk LA; Shevchenko LI
    Ukr Biokhim Zh; 1976; 48(4):521-32. PubMed ID: 982623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nodular glomerular lesion: a later stage of diabetic nephropathy?
    Hong D; Zheng T; Jia-qing S; Jian W; Zhi-hong L; Lei-shi L
    Diabetes Res Clin Pract; 2007 Nov; 78(2):189-95. PubMed ID: 17683824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Renal histological lesions in patients with type II diabetes mellitus].
    Castellano I; Covarsí A; Novillo R; Gómez-Martino JR; Ferrando L
    Nefrologia; 2002; 22(2):162-9. PubMed ID: 12085417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Kidney changes in patients with proliferative diabetic retinopathy].
    Stein G; Kresse S; Dietze U; Deufrains A
    Z Gesamte Inn Med; 1984 Jul; 39(13):309-11. PubMed ID: 6485427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Characteristics of the proteinuria in diabetic nephropathy].
    Astrug A; Genov D
    Vutr Boles; 1978; 17(2):72-9. PubMed ID: 77585
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-diabetic renal disease in patients with type 2 diabetes mellitus.
    Prakash J; Sen D; Usha ; Kumar NS
    J Assoc Physicians India; 2001 Apr; 49():415-20. PubMed ID: 11762610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diabetic retinopathy is a poor predictor of type of nephropathy in proteinuric type 2 diabetic patients.
    Prakash J; Lodha M; Singh SK; Vohra R; Raja R; Usha
    J Assoc Physicians India; 2007 Jun; 55():412-6. PubMed ID: 17879494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.